Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deltacel with Low Dose Radiotherapy in Advanced NSCLC or Solid Tumors
NCT06069570Phase 1Recruiting
- Sponsor
- Kiromic BioPharma, Inc.
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KB-GDT-01 in non-small cell lung cancer (NSCLC) and Solid tumors, sponsored by Kiromic BioPharma, Inc. Primary endpoint: Number of participants with Adverse Events (AE) and/or Dose Limiting Toxicities (DLT) at Day 40. Started Nov 2023; status: recruiting.
02
Drugs
KB-GDT-01
03
Conditions
non-small cell lung cancer (NSCLC)Solid tumors
Beyond the preview
Go deeper on NCT06069570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06069570.